TD Waterhouse Canada Inc. Sells 2,340 Shares of Regeneron Pharmaceuticals, Inc. $REGN

TD Waterhouse Canada Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 25.4% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 6,856 shares of the biopharmaceutical company’s stock after selling 2,340 shares during the period. TD Waterhouse Canada Inc.’s holdings in Regeneron Pharmaceuticals were worth $5,292,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Belpointe Asset Management LLC purchased a new position in Regeneron Pharmaceuticals in the fourth quarter valued at about $1,735,000. Krilogy Financial LLC increased its stake in shares of Regeneron Pharmaceuticals by 18.4% during the 4th quarter. Krilogy Financial LLC now owns 2,476 shares of the biopharmaceutical company’s stock worth $1,888,000 after purchasing an additional 385 shares during the last quarter. Earned Wealth Advisors LLC increased its stake in shares of Regeneron Pharmaceuticals by 6.3% during the 4th quarter. Earned Wealth Advisors LLC now owns 671 shares of the biopharmaceutical company’s stock worth $518,000 after purchasing an additional 40 shares during the last quarter. Bayforest Capital Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $303,000. Finally, Atlantic Edge Private Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 6.9% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 1,464 shares of the biopharmaceutical company’s stock worth $1,130,000 after purchasing an additional 95 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN opened at $747.36 on Wednesday. The company has a 50 day moving average of $764.87 and a 200 day moving average of $729.56. The company has a market cap of $79.01 billion, a PE ratio of 17.98, a price-to-earnings-growth ratio of 1.67 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share for the quarter, beating analysts’ consensus estimates of $10.74 by $0.70. The business had revenue of $3.88 billion during the quarter, compared to analyst estimates of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.41% and a return on equity of 13.04%. Regeneron Pharmaceuticals’s revenue was up 2.5% compared to the same quarter last year. During the same period in the previous year, the business earned $12.07 EPS. On average, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.27 EPS for the current year.

Regeneron Pharmaceuticals Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 5th. Stockholders of record on Friday, February 20th were given a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.5%. This is a boost from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. The ex-dividend date was Friday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 1,638 shares of the firm’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $781.33, for a total value of $1,279,818.54. Following the completion of the transaction, the director owned 1,703 shares in the company, valued at $1,330,604.99. This trade represents a 49.03% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $778.53, for a total value of $77,853.00. Following the transaction, the director directly owned 17,803 shares of the company’s stock, valued at $13,860,169.59. The trade was a 0.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 3,774 shares of company stock worth $2,942,738. 7.02% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Friday, March 27th. JPMorgan Chase & Co. boosted their target price on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Zacks Research cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, February 6th. Piper Sandler assumed coverage on Regeneron Pharmaceuticals in a research note on Tuesday, March 31st. They set an “overweight” rating and a $875.00 price target for the company. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $769.00 to $796.00 and gave the stock an “equal weight” rating in a report on Friday, April 10th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $811.96.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.